<DOC>
	<DOCNO>NCT01591551</DOCNO>
	<brief_summary>The purpose study assess impact Natalizumab ( Tysabri ) therapy sleep efficiency , total sleep time sleep latency , Multiple Sclerosis ( MS ) patient receive Natalizumab 6 month relative baseline .</brief_summary>
	<brief_title>NAPS-MS : NAtalizumab Effects Parameters Sleep Patients With Multiple Sclerosis Experiencing Fatigue Sleepiness</brief_title>
	<detailed_description>Natalizumab show positively impact fatigue cognition . The mechanism occur unknown . Change quality sleep one possible etiology finding . This study help elucidate mechanism lead reduce fatigue/sleepiness less cognitive dysfunction MS patient go Natalizumab therapy . Understanding factor may help neurologist good differentiate different therapeutic option MS may impact symptom negatively affect quality life .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Relapsing form multiple sclerosis Able give inform consent commit follow protocol EDSS 0 6.0 Epworth Sleepiness Scale &gt; 9 Modified Fatigue Impact Scale &gt; 30 Fatigue Severity Scale &gt; 4 Age range 18 65 year age Na√Øve Natalizumab Enrolled TOUCH program Severe cognitive impairment Coexisting severe medical condition Inability speak English read Inability give valid informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>